Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

Additionally, a partnership with Ono Pharmaceuticals has been established to develop sapablursen for polycythemia vera, aiming to strengthen Ionis’s market presence. Oppenheimer has maintained ...

Additionally, a partnership with Ono Pharmaceuticals has been established to develop sapablursen for polycythemia vera, aiming to strengthen Ionis’s market presence. Oppenheimer has maintained an ...